Harrow, Inc. HROW
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -42.37%
- 1 year
- -24.81%
- Open
- 29.69
- Prev close
- 29.99
- Mkt cap
- 1.06B
- Vol
- 335.28K
- Avg vol
- 571.02K
- EPS
- -0.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 28.08
- High
- 30.05
- Forward P/E
- 10.19
- Beta
- 0.18
- Short ratio
- 11.49
- Inst. own
- 58.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 33.14
- 200-d avg
- 38.45
- 1y target
- 63.00
News
3 days ago seekingalpha.com
Harrow's Top Two Drugs Alone Can Justify Its Current Valuation
Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large,…
6 days ago globenewswire.com
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its…
3 weeks ago zacks.com
Do Options Traders Know Something About Harrow Stock We Don't?
Investors need to pay close attention to HROW stock based on the movements in the options market lately.
3 weeks ago defenseworld.net
Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research
Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They…
3 weeks ago globenewswire.com
Harrow Closes Acquisition of TYRVAYA®
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for…
1 month ago defenseworld.net
Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One…
1 month ago globenewswire.com
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific…
1 month ago defenseworld.net
Harrow (NASDAQ:HROW) Stock Falls 6.8% – Here’s Why
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The company traded as low as $31.64 and last traded at $30.8280. Approximately 176,792 shares were…
1 month ago defenseworld.net
Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)
Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
1 month ago benzinga.com
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Harrow with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperform rating and announces Price Target of $45.
2 months ago globenewswire.com
Harrow to Participate in Three Investor Conferences in September
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half
Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.
2 months ago benzinga.com
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort.
-
2 months ago benzinga.com
Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study…
2 months ago globenewswire.com
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest…
2 months ago seekingalpha.com
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Harrow Q2 Earnings Call Highlights
Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half…
2 months ago benzinga.com
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26 guidance. Other stocks also down in pre-market.
2 months ago zacks.com
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.
-
2 months ago benzinga.com
Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M Est
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $348.468 million estimate.
-
2 months ago benzinga.com
Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate
Harrow (NASDAQ:HROW) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.21) by 119.05 percent. This is a 453.85 percent decrease over earnings of $0.13…
2 months ago benzinga.com
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.
2 months ago globenewswire.com
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a…
3 months ago globenewswire.com
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026
-
3 months ago benzinga.com
Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To Lucentis
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional…
3 months ago globenewswire.com
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients, SB11 provided…
-
3 months ago benzinga.com
Harrow Presents Three Studies Supporting IHEEZO, Low Viscosity Ocular Anesthetic Gel, And BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTIS At ASRS 2026 Annual Meeting
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl…
3 months ago globenewswire.com
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three…
3 months ago benzinga.com
8 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
4 months ago benzinga.com
Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar…
4 months ago globenewswire.com
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar
4 months ago benzinga.com
Harrow Adds Another Piece To Ophthalmology Strategy
Harrow relaunches Verkazia for VKC treatment, targeting pediatric eye disease with a steroid-sparing therapy option.
-
4 months ago benzinga.com
Harrow Re-Launches Steroid-Sparing VERKAZIA For Vernal Keratoconjunctivitis, Targeting Underlying Inflammatory Mechanisms In Pediatric Patients
VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access…
5 months ago benzinga.com
Alpha Buying: When CEOs and CFOs Buy Together
Alpha Buying: When CEOs and CFOs Buy Together
-
5 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Harrow, Lowers Price Target to $88
Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lowers the price target from $91 to $88.
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 months ago benzinga.com
Transcript: Harrow Q1 2026 Earnings Conference Call
Transcript: Harrow Q1 2026 Earnings Conference Call
5 months ago benzinga.com
AST SpaceMobile Posts Downbeat Q1 Results, Joins Hims & Hers Health, Gitlab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures lower, Nasdaq down 200 points. AST SpaceMobile shares dip 11% after reporting worse-than-expected financial results.
5 months ago benzinga.com
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
5 months ago benzinga.com
Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $351.380M Est
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $351.380 million estimate.
-
5 months ago benzinga.com
Harrow Q1 EPS $(0.74) Misses $(0.39) Estimate, Sales $44.203M Miss $52.420M Estimate
Harrow (NASDAQ:HROW) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.39) by 89.74 percent. This is a 94.74 percent decrease over losses of $(0.38)…
-
6 months ago benzinga.com
LogiCare3PL Selected As Distribution Partner For Harrow's Portfolio Of Ophthalmic Disease Management Solutions
LogiCare3PL today announced it has been selected by Harrow, Inc. (NASDAQ:HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions. Effective February 1, 2026,…
-
6 months ago benzinga.com
B. Riley Securities Reiterates Buy on Harrow, Lowers Price Target to $65
B. Riley Securities analyst Mayank Mamtani reiterates Harrow (NASDAQ:HROW) with a Buy and lowers the price target from $74 to $65.
-
7 months ago benzinga.com
Harrow Announces Additional $50M Note Offering; 8.625% Senior Unsecured Notes Due 2030
The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that…
8 months ago benzinga.com
These Analysts Revise Their Forecasts On Harrow Following Q4 Results
These Analysts Revise Their Forecasts On Harrow Following Q4 Results
-
8 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Harrow, Lowers Price Target to $91
Cantor Fitzgerald analyst Steve Seedhouse maintains Harrow (NASDAQ:HROW) with a Overweight and lowers the price target from $94 to $91.